We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics
Read MoreHide Full Article
Amgen Inc. (AMGN - Free Report) announced that it has entered into a research collaboration agreement with Massachusetts-based private biotech Generate Biomedicines to discover and develop protein therapeutics for five clinical targets in several therapeutic areas and multiple modalities.
Under the deal, Generate’s machine-learning-enabled technology generative biology platform will be leveraged to discover and create novel protein sequences with optimal therapeutic properties.
Per the deal for the five initial programs, Amgen will make an upfront payment of $50 million to Generate Biomedicines. Amgen will pay around $370 million in future milestones as well as royalties up to low double digits for each of the five programs. Amgen will have the option to nominate up to five more programs at additional cost.
Shares of Amgen have lost 5.6% in the past year compared with the industry’s decline of 30%.
Image Source: Zacks Investment Research
Amgen remains focused on driving growth and boosting its pipeline through deals and acquisitions.
Amgen entered into an agreement with Japanese pharmaceutical company, Kyowa Kirin Co, to jointly develop and commercialize KHK4083 for the treatment of atopic dermatitis (“AD”) in June 2021. KHK4083 is a potential first-in-class anti-OX40 fully-human monoclonal antibody being developed by Kyowa Kirin for AD and other potential autoimmune diseases.
In October 2021, Amgen signed a strategic collaboration with Neumora Therapeutics to advance neuroscience discovery. The companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities to advance innovative medicines for brain disease.
Also, in 2021, Amgen acquired Five Prime Therapeutics, which added late-stage cancer candidate bemarituzumab to Amgen’s pipeline. Amgen completed the acquisition of small private cancer biotech Teneobio in October 2021. The acquisition included Teneobio's proprietary bispecific and multispecific antibody technologies. The acquisition added TNB-585, a phase I bispecific T cell-engager, for the treatment of metastatic castrate-resistant prostate cancer to Amgen’s pipeline.
Image: Shutterstock
Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics
Amgen Inc. (AMGN - Free Report) announced that it has entered into a research collaboration agreement with Massachusetts-based private biotech Generate Biomedicines to discover and develop protein therapeutics for five clinical targets in several therapeutic areas and multiple modalities.
Under the deal, Generate’s machine-learning-enabled technology generative biology platform will be leveraged to discover and create novel protein sequences with optimal therapeutic properties.
Per the deal for the five initial programs, Amgen will make an upfront payment of $50 million to Generate Biomedicines. Amgen will pay around $370 million in future milestones as well as royalties up to low double digits for each of the five programs. Amgen will have the option to nominate up to five more programs at additional cost.
Shares of Amgen have lost 5.6% in the past year compared with the industry’s decline of 30%.
Amgen remains focused on driving growth and boosting its pipeline through deals and acquisitions.
Amgen entered into an agreement with Japanese pharmaceutical company, Kyowa Kirin Co, to jointly develop and commercialize KHK4083 for the treatment of atopic dermatitis (“AD”) in June 2021. KHK4083 is a potential first-in-class anti-OX40 fully-human monoclonal antibody being developed by Kyowa Kirin for AD and other potential autoimmune diseases.
In October 2021, Amgen signed a strategic collaboration with Neumora Therapeutics to advance neuroscience discovery. The companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities to advance innovative medicines for brain disease.
Also, in 2021, Amgen acquired Five Prime Therapeutics, which added late-stage cancer candidate bemarituzumab to Amgen’s pipeline. Amgen completed the acquisition of small private cancer biotech Teneobio in October 2021. The acquisition included Teneobio's proprietary bispecific and multispecific antibody technologies. The acquisition added TNB-585, a phase I bispecific T cell-engager, for the treatment of metastatic castrate-resistant prostate cancer to Amgen’s pipeline.
Zacks Rank & Stocks to Consider
Amgen currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the drug/biotech sector include PaciraBioSciences, Inc. (PCRX - Free Report) , Precision BioSciences, Inc. (DTIL - Free Report) and AnaptysBio, Inc. (ANAB - Free Report) , all sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Pacira’s earnings estimates have been revised 5.7% upward for 2022 over the past 60 days.
Pacira’s earnings have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Precision BioSciences’ loss per share estimates have narrowed 20.1% for 2022, over the past 60 days.
Precision BioSciences’ earnings surpassed estimates in each of the trailing four quarters.
AnaptysBio’s loss per share estimates have narrowed 1.6% for 2022, over the past 60 days. The stock has rallied 33.4% in the past year.
AnaptysBio’s earnings surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.